WallStSmart

Alpha Cognition Inc (ACOG)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alpha Cognition Inc generates 1359% more annual revenue ($10.83M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -234.8%. ACOG earns a higher WallStSmart Score of 28/100 (F).

ACOG

Avoid

28

out of 100

Grade: F

Growth: 5.7Profit: 2.0Value: 5.0Quality: 5.8
Piotroski: 4/9Altman Z: 0.72

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACOG2 strengths · Avg: 8.0/10
Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
20.7%8/10

Revenue surging 20.7% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ACOG4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$138.05M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-43.8%2/10

ROE of -43.8% — below average capital efficiency

Free Cash FlowQuality
$-11.80M2/10

Negative free cash flow — burning cash

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ACOG

The strongest argument for ACOG centers on Price/Book, Revenue Growth. Revenue growth of 20.7% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ACOG

The primary concerns for ACOG are EPS Growth, Market Cap, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

ACOG profiles as a growth stock while RVMD is a value play — different risk/reward profiles.

ACOG carries more volatility with a beta of 2.39 — expect wider price swings.

ACOG is growing revenue faster at 20.7% — sustainability is the question.

ACOG generates stronger free cash flow (-12M), providing more financial flexibility.

Bottom Line

ACOG scores higher overall (28/100 vs 24/100) and 20.7% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alpha Cognition Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Alpha Cognition Inc. is a forward-thinking biopharmaceutical company dedicated to pioneering innovative therapies for neurodegenerative conditions, with a strong emphasis on Alzheimer's disease. Its lead candidate, ACOG-100, targets cognitive enhancement, addressing significant unmet needs within the aging demographic. By harnessing a proprietary neuroscience platform and robust research and development initiatives, Alpha Cognition is positioned to drive advancements in patient care. As the company advances its clinical pipeline and explores additional therapeutic avenues, it represents a compelling investment prospect for institutional investors seeking exposure to transformative innovations in the healthcare sector.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?